ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)

ECOG-ACRIN 综合白血病转化科学中心 (LTSC)

• 批准号: 10579282
• 负责人: Omar Abdel-Wahab
• 金额: $ 89.27万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-07 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10579282
• 关键词: Acceleration; Acute leukemia; American College of Radiology Imaging Network; Biological Assay; Biological Markers; Biology; CLIA certified; Caring; Center for Translational Science Activities; Classification; Clinic; Clinical; Clinical Investigator; Clinical Trials; Clinical Trials Design; Communities; Correlative Study; Credentialing; Data; Development; Diagnostic Procedure; Disease; Eastern Cooperative Oncology Group; Ensure; Fostering; Funding; Genomics; Goals; Hematologic Neoplasms; Hematopoietic Neoplasms; Immunotherapy; Infrastructure; Laboratories; Laboratory Finding; Laboratory Research; Laboratory Scientists; Laboratory Study; Lead; Leadership; Molecular; Molecular Profiling; Monitor; National Clinical Trials Network; Outcome; Pathogenesis; Patients; Phase; Pilot Projects; Productivity; Protocols documentation; Relapse; Research; Research Design; Research Personnel; Resistance; Resources; Risk; Sampling; Science; System; Technology; Testing; Therapeutic; Translating; Translational Research; Translations; Treatment Efficacy; biomarker discovery; chronic leukemia; clinical care; clinical practice; computing resources; data warehouse; epigenetic profiling; gene discovery; genomic platform; improved outcome; innovation; insight; leukemia; leukemia tissue bank; leukemia treatment; molecular oncology; new therapeutic target; novel; novel marker; novel therapeutic intervention; novel therapeutics; personalized diagnostics; pre-clinical research; predicting response; prognostic; programs; resistance mechanism; response; risk stratification; standard of care; synergism; targeted treatment; translational study; treatment stratification

PROJECT SUMMARY The proposed Leukemia Translational Science Center (LTSC), will generate, coordinate and lead translational studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the Leukemia Translational Laboratory (LTRL) and the Leukemia Tissue Bank (LTB), and a comprehensive Leukemia Data Warehouse. The LTSC is led by R. Levine, A. Melnick, and A. Ferrando. They have developed an extensive track record in translational research leadership and implementation of state-of-the-art correlative studies in leukemia biology. The LTSC is further enhanced through its partnership with the MSK Centers for Molecular Oncology and Center for Hematologic Malignancies, which provide access to high-throughput genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality clinical trials based on the most important science, the LTSC will establish an interaction framework that will attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including access to patient samples and clinical/molecular data, genomic and epigenetic profiling capabilities and analytic platforms, scientific support, and a robust, productive collaborative leukemia research community. In this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the LTSC aims to transform the standard practice of leukemia care with the development and implementation of personalized diagnostic methods, biomarkers and therapies.

项目摘要 拟议的白血病转化科学中心（LTSC）将产生，协调和铅翻译 ECOG-ACRIN和国家临床试验网络（NCTN）中的白血病研究。 LTSC会 作为白血病实验室委员会（LLC）研究的中心枢纽 白血病转化实验室（LTRL）和白血病组织库（LTB）以及全面 白血病数据仓库。 LTSC由R. Levine，A。Melnick和A. Ferrando领导。他们已经发展了 最先进的相关性转化研究领导和实施方面的广泛记录 白血病生物学研究。 LTSC通过与MSK中心的合作伙伴关系进一步增强 分子肿瘤学和血液系统恶性肿瘤中心，可提供高通量 基因组技术，最先进的基因组平台，计算资源以及能力 进行广泛的，经过CLIA认证的临床基因组学测定。为了最大程度地加速高质量 基于最重要的科学的临床试验，LTSC将建立一个交互框架，将 吸引初级和高级临床研究者，实验室科学家，计算生物学家，生物统计学家 和其他人，使他们能够组成协同的研究团队。 LTSC将为试点项目提供资金 跨学科团队开始启动这些项目和大量科学资源，包括 访问患者样品以及临床/分子数据，基因组和表观遗传分析能力以及 分析平台，科学支持和强大的，富有成效的共同白血病研究社区。在 这样，LTSC将确保将翻译科学研究无缝整合到白血病中 临床试验以识别反应/结果的预测因素，识别和测试新疗法，并发展 创新的相关研究以评估对抗白血病疗法的反应。通过这些活动， LTSC旨在通过开发和实施来改变白血病护理的标准实践 个性化诊断方法，生物标志物和疗法。